CzeekV インデックス 活用事例・実践,研究報告など、お役立ち情報をシェアします

論文・技術情報追加のお知らせ

• 論文・技術情報追加のお知らせ

  2025年2月16日～2025年2月22日の間に収集した論文情報を追加しました。

  1. Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database.

  TCEsの安全性に多様な有害事象が確認された

  対象DB：FAERS

  2. Safety of Edaravone in real-world use: analysis based on FDA adverse event reporting system.

  エダラボンで新たな有害事象が確認され管理強化要

  対象DB：FAERS

  3. Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA's adverse event reporting system database.

  ロスバスタチン＋フェノフィブラート併用で筋消化器系AE増加

  対象DB：FAERS

  4. Adverse Events Associated with Inclisiran: A Real-world pharmacovigilance study of FDA adverse event reporting system (FAERS).

  インクリシランに新たな有害事象のシグナルを確認

  対象DB：FAERS

  5. A pharmacovigilance study of olanzapine/samidorphan based on FDA Adverse Event Reporting System (FAERS).

  OLZ/SAMの長期安全性と離脱症候群に注意

  対象DB：FAERS

  6. Post-Marketing Safety Surveillance of Adalimumab, Secukinumab, and Infliximab in Hidradenitis Suppurativa: An Analysis of the FDA Adverse Events Reporting System (FAERS) Database.

  ヒダーデン症治療薬3種の安全性を分析

  対象DB：FAERS

  7. Drug-induced hypokalemia: an analytical study based on real-world drug monitoring data.

  低カリウム血症を引き起こす薬1141種を特定

  対象DB：FAERS

  8. Adverse event profiles of CDK4/6 inhibitors: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database.

  CDK4/6阻害剤で血液障害や心伝導異常のリスク

  対象DB：FAERS

  9. A real-world pharmacovigilance analysis of hepatitis B vaccine using the U.S. Vaccine Adverse Event Reporting System (VAERS) database.

  B型肝炎ワクチンで再生不良性貧血のリスク

  対象DB：FAERS,VAERS

  10. What does real-world data reveal about cangrelor's safety? An analysis of FDA adverse event reporting system (FAERS) database.

  カングレロルで予期せぬ有害事象を確認

  対象DB：FAERS

  11. Assessment of adverse events of the novel antiepileptic drug lamotrigine: a real-world pharmacovigilance study based on FAERS.

  ラモトリギンで新たな有害事象を検出

  対象DB：FAERS

  12. Drug-induced skin ulcer: real-world pharmacovigilance analysis based on the FDA adverse event reporting system.

  32種の薬剤が皮膚潰瘍と関連

  対象DB：FAERS

  13. Potential risk analysis of antipsychotics-related constipation from the FDA Adverse Event Reporting System.

  抗精神病薬の便秘リスクは薬剤で異なる

  対象DB：FAERS

  14. Novel insights into post-marketing AEs associated with bempedoic acid: a comprehensive analysis utilizing the FAERS database.

  ベンペド酸は筋骨格系や肝胆道系に副作用

  対象DB：FAERS

  15. Hepatic Adverse Events with CDK4/6 Inhibitors: A systematic review combining meta-analysis and FAERS Database.

  CDK4/6阻害薬は肝毒性を引き起こす

  対象DB：FAERS

  16. Toxicity spectrum of taxanes: A safety analysis from pre-marketing to post-marketing.

  タキサン系は白血球減少と脱毛が多発

  対象DB：FAERS

  17. Effect of erythropoiesis-stimulating agents on malignant neoplasms: FAERS database and Mendelian randomization.

  ESAsは特定の悪性腫瘍と関連の可能性

  対象DB：FAERS

  18. Disproportionality analysis of Raynaud's phenomenon associated with calcitonin gene-related peptide inhibitors using the Food and Drug Administration adverse event reporting system.

  CGRP阻害薬はレイノー現象と関連の可能性

  対象DB：FAERS,KAERS

  19. A pharmacovigilance analysis of abrocitinib-related skin adverse events based on the FDA Adverse Event Reporting System (FAERS).

  アブロシチニブは予期せぬ皮膚有害事象と関連

  対象DB：FAERS

  20. Updated insights on levetiracetam-associated severe cutaneous adverse reactions: a real-world pharmacovigilance analysis.

  LEVはSCARsと関連し、特に初週に多発

  対象DB：EudraVigilance,FAERS

  21. PPIs effect in EGFR-TKI-associated interstitial lung diseases in patients with non-small cell lung cancer.

  EGFR-TKIと特定PPIの併用でILDリスク増加

  対象DB：FAERS

  22. What three years of COVID-19 vaccine administration reveals about the incidence of shoulder injury related to vaccine administration (SIRVA).

  SIRVAの発生率は10万回接種あたり3.7件

  対象DB：EudraVigilance

  23. Evaluation of Interstitial Lung Disease Complications Caused by Biologic Agents Using a Spontaneous Adverse Drug Reaction Reporting Database.

  生物学的製剤使用でILDリスク、特にTNF阻害剤に注意

  対象DB：VigiBase

  24. Clozapine pharmacovigilance in Croatia: Underreporting of specific adverse drug reactions and excellent reporting of suicide attempts.

  クロアチアのクロザピン有害事象報告は過少、 自殺関連報告は過大

  対象DB：VigiBase

  25. Cardiovascular Toxicity Profile of Macrolides Investigated Using VigiBase Data: A Pharmacovigilance Study.

  マクロライド系抗菌薬の心血管毒性リスクを比較

  対象DB：VigiBase

  26. Analysis of sleep medication-induced parasomnias using the Japanese Adverse Drug Event Report database.

  非ベンゾ系とオレキシン阻害薬は夢遊病を誘発

  対象DB：JADER

  27. Association of cirrhosis severity with outcomes after hip fracture repairs: A propensity-score matched analysis using a large inpatient database.

  重度肝硬変患者の股関節骨折手術は死亡率増加

  対象DB：DPC

  28. Benchmarking broad-spectrum antibiotic use in older adult pneumonia inpatients: a risk-adjusted smoothed observed-to-expected ratio approach.

  広域抗菌薬の使用を病院間で評価し改善策を提案

  対象DB：DPC

  29. Safety of Non-robotic Transoral Surgeries for Pharyngolaryngeal Cancer: A Risk Factor Analysis of Complications Using Nationwide Claims Data.

  NRTOSは合併症と死亡率が低く、安全な手技

  対象DB：DPC

  30. Persistence to growth hormone treatment and clinical characteristics of pediatric patients with growth hormone deficiency: A retrospective cohort study of data from the Japan Medical Data Center claims database.

  日本のpGHD患者はGHRTを概ね継続するが、早期診断が重要

  対象DB：JMDC

  31. Modifiable factors to achieve target blood pressure in hypertensive participants.

  生活習慣改善が血圧管理に有効で、高齢者や重症者は医療相談が必要

  対象DB：NDB

  32. Prevalence and risk of complications in untreated patients with adult growth hormone deficiency.

  GH未治療のAGHD患者は合併症リスクが高い

  対象DB：MDV

  33. Disease burden, healthcare resource utilisation, and treatment patterns in patients with newly diagnosed myasthenia gravis in England: A retrospective cohort study.

  MG患者は高い疾病負担と医療利用率を示す

  対象DB：CPRD

  34. Association between diabetes self-management education attendance, hospital admissions and mortality in type 2 diabetes: A cohort analysis protocol.

  DSME受講が2型糖尿病患者の入院や死亡率に与える影響を検討する

  対象DB：CPRD

  35. General practice antibiotic prescriptions attributable to respiratory syncytial virus by age and antibiotic class: an ecological analysis of the English population.

  RSVは英国の抗生物質処方の2.1%を占める

  対象DB：CPRD

  36. Validation of Clinical Practice Research Datalink (CPRD) Aurum Mother-Baby Link.

  CPRD Aurumの母子リンクは高い精度を示す

  対象DB：CPRD

  37. Safety and effectiveness of anticoagulation therapy in older people with atrial fibrillation during exposed and unexposed treatment periods.

  抗凝固療法未使用は脳卒中・死亡リスク増加

  対象DB：CPRD

  38. Comparison of Efficacies of a Blonanserin Transdermal Patch and Blonanserin Oral Formulation for Psychiatric Symptoms in Patients With Schizophrenia Treated With Laxatives Using a Japanese Claims Database.

  下剤使用患者の統合失調症治療で経皮薬と経口薬の入院リスクに差はなし

  対象DB：DeSC

  39. A Cost-Effectiveness Analysis for the Combination of Universal Screening at 9-10 Years Old and Reverse Cascade Screening of Relatives for Familial Hypercholesterolemia in Japan.

  家族性高コレステロール血症の検診は費用対効果が高い

  対象DB：DeSC

  タグ:

  • お知らせ
  • 論文

• お問合わせ

  お問合わせ

  検索

  サイト内検索・論文検索

  

  検索

  サイト内 論文

  キーワード

  PubmedID
  Abstract
  Title
  Journal
  Date (PubMed追加日)	～
  Author
  タクソノミー検索	タクソノミー検索 CAERS CARD CPRD CVAR CVARD DeSC DPC EHR ESP-VAERS EudraVigilance FAERS Fibroblasts FPVD GPRD Ionizing JADER JMDC KAERS KIDS-KAERS KIDS-KD MDV NDB Nickel Pharmacoepidemiology Radiation RWE THIN Unknown VAERS VigiBase インフォメーション スコア値 スコア指標 総合ランキング 閾値

  

  メルマガ登録

  購読申し込み